Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
November 01, 2023 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
October 23, 2023 10:30 ET
|
Novartis Pharma AG
Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per updated...
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
October 05, 2023 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Celcuity to Host Virtual Science Day for Investors
September 07, 2023 16:05 ET
|
Celcuity Inc.
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor typesDiscussion of the...
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
August 22, 2023 16:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
August 22, 2023 16:01 ET
|
Celcuity Inc.
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 ...
Orion Group Half-Year Financial Report 1–6/2023
July 17, 2023 05:00 ET
|
Orion Oyj
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2023 17 JULY 2023 at 12:00 EEST Orion Group Half-Year Financial Report 1–6/2023 This is a summary or Orion’s Half-Year Financial Report...
Orion invests EUR 30 million to increase production capacity in Finland
June 28, 2023 01:00 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 28 June 2023 at 08.00 EEST Orion invests EUR 30 million to increase production capacity in Finland In response to the increasing demand for its products, Orion...
Orion Group Interim Report 1–3/2023
April 27, 2023 05:00 ET
|
Orion Oyj
ORION CORPORATION INTERIM REPORT 1–3/2023 27 APRIL 2023 at 12:00 EEST Orion Group Interim Report 1–3/2023 This is a summary or Orion’s Interim Report 1–3/2022. The complete report is...
Orion ja Bayer laajentavat darolutamidin kliinistä kehitysohjelmaa eturauhassyövän alueella
March 23, 2023 09:00 ET
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 23.3.2023 klo 15.00 Orion ja Bayer laajentavat darolutamidin kliinistä kehitysohjelmaa eturauhassyövän alueella Vaiheen III -tutkimus...